- Trials with a EudraCT protocol (51)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (3)
51 result(s) found for: Alendronate.
Displaying page 2 of 3.
EudraCT Number: 2020-005343-23 | Sponsor Protocol Number: ADAIDO | Start Date*: 2021-05-28 | |||||||||||
Sponsor Name:IRCCS ISTITUTO ORTOPEDICO GALEAZZI S.P.A | |||||||||||||
Full Title: Effect of the antiresorptive treatment with alendronate versus no treatment after denosumab and aromatase inhibitors discontinuation in low fracture risk osteopenic postmenopausal women with non me... | |||||||||||||
Medical condition: post-menopausal osteoporosis in women with non-metastatic hormonal receptor positive (HR+) breast cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004819-37 | Sponsor Protocol Number: APART_2014 | Start Date*: 2015-04-16 | |||||||||||
Sponsor Name:University College Dublin | |||||||||||||
Full Title: A multi-centre, prospective, randomised trial of short course alendronate therapy or placebo combined with vitamin D and calcium to prevent loss of bone mineral density in antiretroviral-naïve, HIV... | |||||||||||||
Medical condition: Human immunodeficiency virus (HIV) infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) DK (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005271-15 | Sponsor Protocol Number: 20050179 | Start Date*: 2007-07-18 |
Sponsor Name:Amgen Inc | ||
Full Title: A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment with Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women with Low Bone Mineral De... | ||
Medical condition: Postmenopausal osteoporosis /osteopenia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2006-002732-22 | Sponsor Protocol Number: CL3-12911-019 | Start Date*: 2006-09-08 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
Full Title: A double-blind, multicentric, multinational randomised study to assess the effects of two years administration of 2g per day of strontium ranelate versus alendronate 70mg per week in women with pos... | |||||||||||||
Medical condition: Treatment of postmenopausal Osteoporosis to reduce the risk of hip and vertebral fractures | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005688-18 | Sponsor Protocol Number: Paw1 | Start Date*: 2016-05-25 | |||||||||||
Sponsor Name:Department of Hematology, Aalborg University Hospital | |||||||||||||
Full Title: A randomized controlled trial of alendronate as preventive treatment against the development of gluco-corticoid-induced osteoporosis in patients being treated for malignant lymphoma | |||||||||||||
Medical condition: Age ≥ 18 years. Patients with new diagnosis or recurrence of lymphoma, which is expected to be treated with one of the listed chemotherapy regimens. Expected lifespan ≥2 years | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000675-90 | Sponsor Protocol Number: 20160397 | Start Date*: 2017-05-30 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: A Phase 3b, Multicenter, Randomized, Double-blind, Parallel Group, Alendronate-Controlled Study in Postmenopausal Women with Osteoporosis Previously Treated with Romosozumab Followed by Alendronate... | |||||||||||||
Medical condition: Postmenopausal osteoporosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) LT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000900-17 | Sponsor Protocol Number: ejude001 | Start Date*: 2007-02-13 |
Sponsor Name:The University of Manchester [...] | ||
Full Title: A randomised double-blind placebo controlled trial of the oral bisphosphonate, Alendronate, plus intravenous pamidronate, in active diabetic Charcot neuroarthropathy (CN). | ||
Medical condition: Charcot neuroarthropathy Code: E10.6 Insulin + M14.6 Code: E11.6 Insulin + M14.6 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2009-015058-38 | Sponsor Protocol Number: OR09/9018 | Start Date*: 2010-10-22 |
Sponsor Name:University of Leeds | ||
Full Title: Improving the outcome for patients after osteoporotic femoral fractures | ||
Medical condition: OSTEOPOROTIC FEMORAL FRACTURE | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2011-000290-31 | Sponsor Protocol Number: 2011.1.42 | Start Date*: 2011-12-27 |
Sponsor Name:Evangelisches Krankenhaus Lutherhaus gGmbH | ||
Full Title: Comparison of the effect of an ongoing treatment with alendronate or a drug holiday on the fracture risk in osteoporotic patients with a bisphosphonate long term therapy | ||
Medical condition: Osteoporosis (DXA-T-Score <-2,0 at lumbar spine, total hip or femur neck OR previous low trauma vertebral fractures) at high fracture risk | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2007-001509-11 | Sponsor Protocol Number: CL3-12911-030 | Start Date*: 2007-10-31 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
Full Title: A double-blind, multicentric, multinational randomised study to assess the effects of two years administration of 2 g per day of strontium ranelate versus alendronate 70 mg per week in women with p... | |||||||||||||
Medical condition: Post-menopausal osteoporosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: SE (Completed) IT (Completed) DE (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002342-19 | Sponsor Protocol Number: 07/05/ALE/TP4 | Start Date*: 2005-07-07 |
Sponsor Name:Zentiva, a.s. | ||
Full Title: A multicentre, open label study to evaluate the safety and efficacy of Alendros 70 therapy administered 70mg once a week in women with postmenopausal osteoporosis | ||
Medical condition: postmenopausal osteoporosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-005445-32 | Sponsor Protocol Number: LA-II-02 | Start Date*: 2016-06-24 | ||||||||||||||||
Sponsor Name:BIOrest, Ltd. | ||||||||||||||||||
Full Title: The BLADE-PCI Trial (PHASE IIB LIPOSOMAL ALENDRONATE STUDY): Biorest Liposomal Alendronate Administration for Diabetic Patients Undergoing Drug-Eluting Stent Percutaneous Coronary Intervention | ||||||||||||||||||
Medical condition: PCI (percutaneous coronary intervention) for angina, silent ischemia or non-STEMI in patients with diabetes mellitus. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005581-39 | Sponsor Protocol Number: CL3-12911-025 | Start Date*: 2007-04-02 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
Full Title: A double-blind, multicenter, international randomised study to assess the effects of 6 months or 12 months administration of 2g per day of strontium ranelate versus alendronate 70mg per week on bo... | |||||||||||||
Medical condition: Treatment of postmenopausal Osteoporosis to reduce the risk of hip and vertebral fractures | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) HU (Completed) NL (Completed) CZ (Completed) IT (Completed) DK (Completed) EE (Completed) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005678-36 | Sponsor Protocol Number: 06-APR-02 | Start Date*: 2008-07-03 |
Sponsor Name:CHU de Nice | ||
Full Title: Oral alendronate for osteoporosis treatment in non-walking children with cerebral palsy | ||
Medical condition: osteoporosis treatment in non-walking children with cerebral palsy | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: FR (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-004903-15 | Sponsor Protocol Number: 2020-004903-15 | Start Date*: 2022-04-20 |
Sponsor Name:University of Alabama at Birmingham | ||
Full Title: Denosumab (DMAB) Discontinuation and Switching Study in Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study | ||
Medical condition: Glucocorticoid-Induced Osteoporosis (GIOP) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-004840-21 | Sponsor Protocol Number: RISED_C_00935 | Start Date*: 2007-04-23 | |||||||||||
Sponsor Name:sanofi-aventis Netherlands B.V. | |||||||||||||
Full Title: Bone Histomorphometry, Microarchitecture and Matrix Structure and Properties in Patients Receiving Long-term Risedronate Treatment | |||||||||||||
Medical condition: The objective of this study is to collect data on bone histomorphometry, architecture, turnover and material properties from iliac crest biopsies taken from postmenopausal women after > 5 year rise... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001703-11 | Sponsor Protocol Number: CZOL446HDE31 | Start Date*: 2006-09-27 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: A multi-center, randomized, open-label, controlled, one-year trial to measure the effect of zoledronic acid and alendronate on bone metabolism in post menopausal women with osteopenia and osteoporosis | |||||||||||||
Medical condition: osteopenia/osteoporosis in postmenopausal women | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004738-33 | Sponsor Protocol Number: STH 14463 | Start Date*: 2007-03-21 | |||||||||||
Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust | |||||||||||||
Full Title: Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential Effects. Subtitle: A 2-year randomised parallel group trial of alendronate, ibandronate and risedronate for postmeno... | |||||||||||||
Medical condition: Osteoporosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006064-32 | Sponsor Protocol Number: FP-005-IM | Start Date*: 2008-02-21 | |||||||||||
Sponsor Name:Nycomed Danmark Aps | |||||||||||||
Full Title: Ensayo clínico de fase IV, internacional, multicéntrico, aleatorizado, doble ciego, doble enmascaramiento, de grupos paralelos, de 24 semanas, que estudia los cambios en el dolor lumbar relacionado... | |||||||||||||
Medical condition: Primary Postmenopausal Osteoporosis Osteoporosis postmenopáusica primaria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Completed) FR (Completed) DE (Completed) IT (Completed) GB (Prematurely Ended) IE (Completed) GR (Completed) DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-008257-30 | Sponsor Protocol Number: 0822-042 | Start Date*: 2009-03-31 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: Estudio en fase IIa aleatorizado, doble ciego, controlado con placebo para evaluar los efectos de odanacatib (MK-0822) sobre la densidad mineral ósea (DMO) y la seguridad general en el tratamiento ... | |||||||||||||
Medical condition: Osteoporosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Completed) CZ (Completed) DE (Completed) BE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
